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ABSTRACT The complex, multistep aggregation kinetic and structural behavior of human recombinant interleukin-1 receptor
antagonist (IL-1ra) was revealed and characterized by spectral probes and techniques. At a certain range of protein concentra-
tion (12–27 mg/mL) and temperature (44–48C), two sequential aggregation kinetic transitions emerge, where the second tran-
sition is preceded by a lag phase and is associated with the main portion of the aggregated protein. Each kinetic transition is
linked to a different type of aggregate population, referred to as type I and type II. The aggregate populations, isolated at a series
of time points and analyzed by Fourier-transform infrared spectroscopy, show consecutive protein structural changes, from intra-
molecular (type I) to intermolecular (type II) b-sheet formation. The early type I protein spectral change resembles that seen for IL-
1ra in the crystalline state. Moreover, Fourier-transform infrared data demonstrate that type I protein assembly alone can undergo
a structural rearrangement and, consequently, convert to the type II aggregate. The aggregated protein structural changes are
accompanied by the aggregate morphological changes, leading to a well-deﬁned population of interacting spheres, as detected
by scanning electron microscopy. A nucleation-driven IL-1ra aggregation pathway is proposed, and assumes two major activa-
tion energy barriers, where the second barrier is associated with the type I/ type II aggregate structural rearrangement that, in
turn, serves as a pseudonucleus triggering the second kinetic event.INTRODUCTION
Aggregation is a dominant degradation pathway of proteins,
and can occur during all stages of protein therapeutics pro-
cessing and storage (1–4). The aggregation of proteins and
their deposition into amorphous precipitates or insoluble fi-
brils were also linked to a number of amyloid diseases, in-
cluding Alzheimer’s and Parkinson’s disorders (5–7). The
aggregation phenomenon can be caused by protein structural
changes or by colloidal effects affecting protein-protein in-
teractions (8–10). Such events can occur via a simple diffu-
sion-limited mechanism (11,12), or may involve nucleation
as the primary stage for the further growth and propagation
of aggregates (13–15). In previous studies, it became evident
that proteins with a dominating b-sheet content are prone to
aggregation (16,17), and can self-assemble into either amor-
phous precipitates or well-defined fibrils (18–20). The aggre-
gation process is also sensitive to a wide range of factors
such as protein concentration, hydrophobicity, and charge,
as well as solution pH, ionic strength, and temperature
(21–25). Despite the critical importance of protein-aggrega-
tion problems, the mechanistic details of the aggregation pro-
cess, including the relationship between kinetic, structural,
and gross morphological changes, are poorly understood.
Characterizing the different types of aggregates and mecha-
nisms of aggregation could help in combating the aggregates
that may pose problems in terms of safety, efficacy, and im-
munogenicity in vivo, as well as in developing better thera-
peutic protein formulation strategies.
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0006-3495/09/01/0199/10 $2.00The use of bioanalytic tools to study the kinetic and struc-
tural mechanisms of protein aggregation has evolved over
the years (26–28). Size-exclusion chromatography is typi-
cally used to quantify the amount of protein-aggregated
species and to identify the various soluble forms (dimer,
tetramer, or higher species) of aggregates. Other analytical
tools, such as dynamic light scattering, analytical ultracentri-
fugation, field-flow fractionation, and mass spectrometry,
can also provide insights into the nature and sizes of soluble
aggregates. However, most of these techniques are difficult
to apply when it comes to a kinetic growth characterization
of significantly larger, insoluble aggregates, and when the
aggregation process goes to completion within a short (10–
100 min) time.
Highly concentrated human interleukin-1 receptor antago-
nist (IL-1ra) has the property of aggregating at elevated tem-
peratures, and it can be used as a suitable model for studying
aggregation mechanisms of small b-sheet proteins that can
occur without protein global unfolding (25,29). It is a 17-
kDa member of the IL-1/fibroblast growth factor family of
proteins, and is a natural IL-1 blocker that plays an important
regulatory role in the inflammation and functioning of the
adaptive immune system (30). The protein tertiary structure
exhibits a b-trefoil topology (31) and consists of 12 antipar-
allel b-strands, six of which are arranged in the form of a
b-barrel (32,33). In this study, we demonstrate the use of a
previously established light-scattering technique (25,34–36)
to identify distinct IL-1ra aggregate populations and to
analyze their kinetic growth behavior. Then, with additional
optical methods, we obtain the structural and morphological
doi: 10.1016/j.bpj.2008.10.002
200 Krishnan and Raibekascharacteristics of isolated time-dependent aggregate species.
It was found that the aggregation behavior of IL-1ra emerges
as a series of sequential kinetic and structural events that,
taken together, suggest a multistep aggregation pathway
for this protein at elevated temperatures.
MATERIALS AND METHODS
Purified recombinant human IL-1ra in 10 mM sodium citrate, 140 mM NaCl,
and 0.5 mM EDTA, pH 6.5 (CSE buffer), was supplied by an Amgen
manufacturing facility as a 220-mg/mL solution. Thioflavin T and 4,40-dia-
nilino-1,10–binaphthyl-5,50-disulphonic acid dipotassium salt (bis-ANS)
were from Sigma-Aldrich (St. Louis, MO). All other chemicals were of the
highest grade available.
Aggregation assay
The IL-1ra aggregation assay at a constant, elevated temperature (isothermal
conditions) was performed in a manner similar to that previously described
(25). Typically, 10 mL of IL-1ra stock solution (220 mg/mL protein in CSE
buffer) were diluted with the same buffer to corresponding concentrations,
and filtered through a 0.2-mm filter (mStar LB, Corning, NY). Unless other-
wise specified, the aggregation of IL-1ra was measured using a 96-well
glass-bottom plate (Sensoplate, Grenier Bio-One, Frickenhausen, Germany)
and a temperature-controlled multidetection plate reader (SpectraMax M5,
Molecular Devices, Sunnyvale, CA). According to manufacturer’s specifica-
tions, the SpectraMax M5 provides a photometric range up to four optical
units because of the decreased path length and designed optics. The reported
accuracy/linearity for a 0–2 optical unit range is51%. The sample volume
per well was 190 mL. The plates were covered with lids and incubated in the
spectrophotometer at 44–48C, whereas optical density (OD) was measured
at 450 nm with 1-min intervals and a 3-s automated shaking step between
readings. The shaking step evenly distributes aggregates in the sample well
solution before absorbance reading, and minimizes signal errors, particularly
during the second kinetic transition. Control (no shaking) experiments
showed that the shaking step did not interfere with the protein aggregation
propensity in our experimental conditions. The protein concentration was
estimated using its absorbance at 279 nm and an extinction coefficient of
13,392 M1 cm1 (25). Absorbance readings at 279 nm were corrected by
subtracting the background signal at 650 nm.
Time-dependent aggregates were isolated as follows. The IL-1ra at a con-
centration of 22 mg/mL in CSE buffer was subjected to an aggregation assay
at 47C. The sample volume per assay well was 200 mL. At a specified time
(1000–5200 s), the assay was stopped and the plate was immediately placed
on ice. After a 20-min incubation on ice, the aggregation sample was centri-
fuged (13,000  g, 15 min, 10C), the supernatant was carefully transferred
into a new 1.5-mL centrifuge tube, and if necessary, the supernatant volume
was adjusted with CSE buffer back to the original 200-mL volume. The ag-
gregated protein fraction (expressed as a percentage) was determined using
the difference in absorbance (A280) value between the sample that was not
subjected to the aggregation assay (control) and the time point-derived su-
pernatant. For Fourier-transform infrared spectroscopy (FTIR) and scanning
electron microscopy (SEM) analyses, aggregate pellets were washed with
10  volume of CSE buffer, centrifuged (13, 000  g, 15 min, 10C), and
resuspended with 1  volume of distilled water.
Analysis of aggregate-type populations
Aggregates of IL-1ra were generated at 47C, using the plate-reading assay
described above. The sample was 22 mg/mL IL-1ra in CSE buffer, and the
volume per well was 190 mL. Type I aggregates were generated as the assay
run was stopped at the 2500-sec time point, and the sample plate was imme-
diately placed on ice, whereas type II aggregates were generated using
a 6000-s incubation. Aggregate sample suspensions were centrifuged
Biophysical Journal 96(1) 199–208down (6000  g, 5 min, 12C), resulting in two separate pellets (type I
and type II). Each pellet was resuspended in 200 mL of cold CSE buffer
and transferred into a preweighed Spin-X 0.22-mm centrifuge tube filter (Co-
star, Corning, NY). After centrifugation (6000  g, 3 min, 12C), the filter
unit containing dry, aggregated material was weighed again, and the aggre-
gate net weight was calculated. Next, based on the weight estimates, a
10-mg/mL stock aggregate suspension in CSE for each type I and type II
was made and subsequently used to prepare 1, 2, 4, 6, and 8 mg/mL samples
by dilution with CSE buffer. The OD of sample suspensions was measured
at 450 nm, using a SpectraMax M5 plate reader and a 96-well Sensoplate
glass-bottom plate. The sample volume per well was 200 mL.
Treatment of isolated type I aggregates at 47C
Type I aggregates were generated using 96-well plates and the same condi-
tions as described above, using 22 mg/mL IL-1ra solution in CSE (190 mL
per well, 12 samples) at 47C. After a 2500-s incubation (near the end of the
first aggregation phase), the experiment was stopped and the plate was im-
mediately transferred onto ice. After a 20-min incubation on ice, samples
were pooled and centrifuged (13,000  g, 7 min, 10C), and the supernatant
was discarded. The pellet was washed with 400 mL cold CSE buffer, centri-
fuged as described above, and resuspended in 100 mL of cold CSE buffer. A
50-mL aliquot of type I aggregate suspension from the previous step was
subjected to a 40-min incubation at 47C, using a programmed thermal incu-
bator (Mastercycler, Eppendorf, Hamburg, Germany). The sample was then
cooled down to 4C and used for FTIR analysis. The other untreated 50-mL
portion of the sample (stored at 4C) was used as a control.
Dye-tracer assay
This assay was performed using a 96-well glass-bottom plate (Sensoplate)
and a temperature-controlled plate reader, SpectraMax M5 (fluorescence
mode). The sample volume per well was 193 mL. The plate was covered
with a lid and was incubated in the spectrophotometer at 47C, while the
fluorescence emission was monitored at 500 nm (excitation at 420 nm),
with 1-min intervals and a 3-s automated shaking step between readings.
The bottom-well reading mode was used for fluorescence measurements.
The sample solution (per well) was prepared by mixing 190 mL of 22 mg/
mL IL-1ra solution in CSE buffer with either 3 mL of 10 mM thioflavin T or
3 mL of a 0.3 mM bis-ANS stock solution in CSE, to achieve dye/protein
molar ratios of 0.125 and 0.0037, respectively. These ratios were chosen
on the basis of a prescreening study, as described below. First, a set of sam-
ple solutions containing a wide range of dye/protein ratios plus a control (no
dye) was subjected to a standard aggregation assay measuring the OD450
signal. Then a fresh set of samples, with ratios that did not show OD aggre-
gation kinetic deviations from the control, were subjected to a fluorescence-
based aggregation assay (see above). Based on these data, two dye/protein
ratio sets (0.125 and 0.0037) that displayed a mutually comparable fluores-
cence intensity range during the assay, and therefore could be run in a single
experiment, were chosen for the main study. In a separate experiment, dye
selectivity was assessed using the above ratios for thioflavin T and bis-
ANS. The sample solutions (in triplicates) were prepared as above, the ag-
gregation assay was performed for 110 min (6600 s), and the aggregates
were separated from the soluble protein fraction by centrifugation
(13,000 g, 10 min, room temperature). The measured volume of the super-
natant (soluble fraction) was 160 mL, so the aggregate fraction was also re-
suspended in 160-mL CSE buffer, and then the dye-related fluorescence
intensity (excitation at 420 nm; emission at 500 nm) of each soluble and
resuspended aggregate fraction was measured and compared, using the Sen-
soplate and SpectraMax M5 instrument. We determined that the vast major-
ity of fluorescence signal (95% and 99.9% for thioflavin T and bis-ANS,
respectively) was associated with the suspended aggregate fraction. In addi-
tion, the selective binding of thioflavin T to the aggregate fraction was
independently confirmed with fluorescence-based microscopy, using a BX51
system microscope equipped with a fluorescence illuminator (Olympus
Corp., Melville, NY).
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A 2-mL solution of 220 mg/mL IL-1ra in CSE buffer was dialyzed against
3.5 L of water at 4C, using a Slide-A-Lyzer 10 K dialysis unit (Pierce,
Rockford, IL). After 3 days of dialysis, the sample became partially precip-
itated or cloudy. Next, the sample was removed from the dialysis unit,
immediately placed on ice, and after a 20-min incubation on ice, was centri-
fuged (3000  g, 5 min, 6C). The supernatant was discarded, and the
pellet was resuspended in 4 mL of ice-cold water and centrifuged under
the above conditions (wash step). The wash step was applied one more
time, the supernatant (water) was discarded, and the pellet was placed in
100-mL ice-cold water and stored at 4C until further use. The crystalline na-
ture of the precipitate was confirmed by both SEM and transmission electron
microscopy.
Fourier-transform infrared (FTIR) spectroscopy
The FTIR spectra of the native and aggregated protein fractions in CSE
buffer were acquired using a Bomem Prota infrared spectrometer (ABB
USA, Norwalk, CT). Samples were placed in a BioTools (Jupiter, FL) liquid
sampling cell, equipped with CaF2 windows that provided a 6-mm path
length. For each spectrum, a 128-scan interferogram was collected in sin-
gle-beam mode, with a 4-cm1 resolution. All second-derivative spectra
were baseline-corrected using the instrument software, based on the method
of Dong and Caughey (37), and were area-normalized under the second-de-
rivative amide I region, at 1600–1700 cm1 (38).
Scanning electron microscopy (SEM)
A sample volume of 10 mL for each preparation was deposited onto SEM
stubs covered with double-sided adhesive tape. The droplet was spread
across the surface of the tape, using the pipette tip, and was allowed to
air-dry. The stubs were then placed into the vacuum chamber of a Pelco
SC-7 sputter-coating device (Ted Pella, Redding, CA), and the chamber was
evacuated. The samples were conductance-coated with gold-palladium
under standard conditions, and were examined using a scanning electron
microscope (model ESEM XL30, FEI Co., Hillsboro, OR) at 5 or 10 kV. Con-
trol experiments with the native protein alone did not reveal any aggregates.
Aggregation rate analysis
The observed rate of aggregate formation (n) was determined by the linear
extrapolation of the time-dependent OD450 change within the growth region.
The rate n was obtained from the slope of the plot of steepest part of the
OD450 value change for each aggregation transition versus time (units per
hour) (39). Because protein aggregates had a quantitative linear correlation
with the OD450 change within each transition, but because the relative OD450
change for the same amount of aggregates was greater for the first transition
by a factor of 5.304 (Fig. 1 B), for the transition-based comparative kinetic
analysis, we used normalized first-transition rates (i.e., nn,1st ¼ n1st,obs/
5.304). The reaction order was determined based on the ‘‘method of initial
rates’’ (40), from the slope of the linear fitted ln-ln plot of n versus protein
molar concentration.
RESULTS
IL-1ra aggregation kinetic behavior
A well-defined biphasic aggregation kinetic trace was
observed, using a combination of protein concentrations
(12–27 mg/mL) and incubation temperatures (44–48C).
This phenomenon is illustrated in Fig. 1 A, which shows
an aggregation profile of 22 mg/mL IL-1ra at 47C, as mon-
itored by an OD signal at a 450-nm wavelength (OD450). Atthis temperature and protein concentration, the protein has
a lag phase, followed by a steep growth phase corresponding
to the formation of protein aggregates. After reaching a pla-
teau (at ~2000 s), a second lag phase is evident before the on-
set of the second growth phase that exhibits relatively less
OD450 change compared with the first transition. This is fol-
lowed by the termination phase. The remaining soluble pro-
tein concentration was determined at various time points by
absorbance at 280 nm, and this fraction was subtracted from
the total initial protein to estimate the amount of aggregates
as percentage of total protein (as detailed in Materials and
Methods). The remaining soluble fraction of IL-1ra retained
the physical and structural properties of the native protein ac-
cording to its FTIR spectrum and size-exclusion chromato-
graphic profile (data not shown). Generally, the solution
IL-1ra secondary structure was not perturbed at 44–48C,
according to FTIR (data not shown) and CD (circular dichro-
ism) (at up to 55C) spectral data analyses (25,29).
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FIGURE 1 Aggregation of 22 mg/mL IL-1ra in CSE buffer, pH 6.5, at
47C. (A) Aggregation kinetic profile (solid circles) and corresponding esti-
mates of aggregated protein (solid squares), as described in detail in Mate-
rials and Methods. Five different time points from which aggregates were
collected for further analyses are indicated on kinetic plot. (B) Relationship
between OD450 and amount of suspended aggregate. Plots are shown for iso-
lated aggregate populations associated with first (type I, open circles) and
second (type II, open triangles) kinetic transitions.
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y axis, which illustrates that the aggregated protein corre-
sponding to the first transition of the OD450 aggregation pro-
file (between 1000–2000 s) constitutes only a small fraction
(<5%) of the total protein. On the other hand, the second
transition is responsible for the aggregation of an additional
20% of the total protein, although its relative change in
OD450 signal is ~3 times lower than that observed in the first
transition.
This observation led us to hypothesize that each transition
represents an accumulation of structurally different aggre-
gate populations (i.e., type I and type II aggregates), where
the type II population has the property of scattering less light,
resulting in a lower OD signal. Therefore, in the next step,
the OD450 values of isolated type I and type II aggregate sus-
pensions were compared directly (as detailed in Materials
and Methods). As shown in Fig. 1 B, the OD change displays
a linear dependence on aggregate concentration, regardless
of aggregate type. However, the slope of the type II curve
is ~5 lower than the slope of the type I curve. This is in
agreement with the above kinetic data, supporting the idea
of at least two distinctive aggregate population types formed
during the IL-1ra aggregation process.
Structural and morphological properties
of IL-1ra aggregates
To gain greater insight into protein aggregate populations,
we analyzed the washed insoluble aggregates obtained at
five consecutive time points (Fig. 1 A), using FTIR spectros-
copy. As seen in Fig. 2 A, the second-derivative FTIR spec-
trum of the native IL-1ra in solution exhibits a predominantly
b-sheet structure, with characteristic minima at 1643 cm1
and 1632 cm1. Upon aggregation, the first time point, cor-
responding to the early growth phase of the first transition,
shows a shift from 1643 cm1 (intramolecular b-sheet struc-
ture) to 1632 cm1. This is accompanied by a transition from
1689 cm1 to 1692 cm1, indicating the simultaneous
growth of the intermolecular b-sheet structure (8,37). The
shift of the main peak toward the lower frequency-absorbing
b-sheet structure continues until the end of the first transition.
The third time-point aggregates, taken at the end of the first
transition, displayed broad bands at 1632 cm1 and 1622
cm1, suggesting the presence of both native b-sheet and
nonnative intermolecular b-sheet structures (Fig. 2 B). This
shift also indicates a further growth of IL-1ra aggregates,
as previously demonstrated (41). When the protein aggrega-
tion process enters the second transition (fourth time point),
aggregates show a major growth of the nonnative 1624-cm1
band, as well as the 1685-cm1 band. By the end of the sec-
ond transition (fifth time point), there is a clear shift from the
native structure to the nonnative b-sheet structure. In addi-
tion, the first-transition FTIR spectra produce a well-defined
isosbestic point around 1630 cm1 that is shifted to ~1625
cm1 during the second transition (Fig. 2 B). Taken together,
Biophysical Journal 96(1) 199–208the data suggest two structurally different protein assemblies
within the type I (first transition) and type II (second transi-
tion) aggregates.
Fig. 2 A also shows the FTIR spectrum of the IL-1ra crys-
talline state obtained, as described in Materials and Methods.
The crystalline protein has more of the low-frequency 1632-
cm1 band, probably because of closer packing. This spec-
trum closely resembles the early phase (first time point) of
the first aggregation transition, suggesting that the protein
conformations in crystals and the early type I aggregates
may be similar. One significant difference was that, unlike
aggregates, the crystalline state was reversible, and when
crystals were dissolved in CSE buffer at room temperature,
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FIGURE 2 Second derivative FTIR spectra show protein structural
changes in IL-1ra aggregates isolated at time points indicated in Fig. 1. Di-
rection of spectral change is indicated by arrow. (A) Control native protein in
solution (solid black line), followed by aggregates at first (long red dashed
line), second (medium cyan dashed line), third (short orange dashed line),
fourth (blue dotted and dashed line), and fifth (pink double dotted and
dashed line) time points. Also shown are FTIR data of protein in crystalline
state (green dotted line). (B) Detailed view of overlaid FTIR spectra demon-
strates how type I aggregates (time points 1–3) undergo a consecutive struc-
tural transition and display more of the intramolecular b-sheet structure at
1638–1628 cm1, which is converted into intermolecular b-sheet at 1622
cm1 and 1695 cm1, as seen in type II aggregates (time points 4–5).
Multistep Aggregation of IL-1rathey turned into a protein solution that exhibited a native
(structurally unperturbed) FTIR spectrum (data not shown).
Because the FTIR data indicated a sequential type I/ type
II structural transition of aggregates formed during the pro-
cess, we investigated the structural flexibility of isolated
type I aggregates. The spectrum of type I aggregates collected
at the end of the first transition of 22 mg/mL protein at 47C is
shown in Fig. 3. Aggregates were centrifuged and washed
several times to remove any remaining (unbound) protein in
solution (see Materials and Methods), and were then incu-
bated in suspension at 47C for ~40 min. This treatment re-
sulted in a further structural transition to the nonnative
1622-cm1 and 1692-cm1 intermolecular b-sheet structure,
resembling the spectral shift characteristic of type II aggre-
gates (Figs. 2 and 3), and suggesting that at the end of first
transition, the protein in type I aggregates can undergo a struc-
tural rearrangement. Consequently, this rearrangement could
precede and predetermine the second transition, i.e., could
serve as a pseudonucleation step for the next, type II aggrega-
tion event. The morphological properties of aggregates col-
lected at time points 1–5 were studied using SEM, and the
results are shown in Fig. 4. All aggregates were free of soluble
protein (washed) before examination by SEM. The aggre-
gates at the first time point are essentially dense clusters of
highly fused spherical particles, each of which is ~0.5 mm in
diameter. As the aggregation process progresses, the spheres
continue to develop, possibly because of the independent
growth or the fusion of smaller spheres. By the end of the first
transition (third time point), the spheres approach 1–1.5mm in
diameter. The second transition aggregates (time points 4 and
5) show a significant enlargement of individual spheres, and
in some cases reach more than 3 mm in diameter. Although in-
dividual spherical particles become well-developed and less
fused (defused), they all remain interconnected or chained
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FIGURE 3 IL-1ra second derivative FTIR spectra show protein structural
changes within isolated type I aggregates after incubation at 47C. Overlaid
type I protein-aggregate spectra before (solid line) and after (dashed line) in-
cubation are shown. Reference spectrum of native protein in solution is also
indicated (dotted line). Aggregated protein alone is capable of type I/ type
II structural rearrangement, as indicated by arrow.within the aggregate cluster. As shown in Fig. 1, the second
transition aggregates recruit the major fraction of the soluble
protein, but display a lower relative OD450 change. Taken to-
gether with the FTIR and SEM analyses, these results suggest
a sequential kinetic and structural aggregation process, where
the second transition, as triggered by the first transition, inde-
pendently recruits soluble protein molecules from solution.
This would lead to a predominantly individual aggregate de-
velopment, resulting in chains of partially defused large
spherical particles and, as shown in Fig. 1, less packed aggre-
gate clusters.
We evaluated aggregation kinetics further by using the
fluorescent dyes bis-ANS and thioflavin T as aggregation
kinetic tracers, using similar OD-based assay conditions as
above, but monitoring the dye fluorescence intensity instead.
In this particular case, the initial purpose was to confirm the
biphasic shape of the aggregation kinetic curve, using an al-
ternative, OD-independent mode of detection. The assay was
designed such that the fluorescent dye would interact (coag-
gregate) selectively with the aggregated fraction rather than
with the soluble protein fraction, and therefore would func-
tion as a tracer for the aggregation process. This was
achieved by using a specific dye/protein molar ratio of
0.125 and 0.0037 for thioflavin T and bis-ANS, respectively
(as detailed in Materials and Methods), resulting in ~155-mM
thioflavin T and 4.7-mM bis-ANS assay sample solutions.
We should note that, according to Roy et al. (41), although
bis-ANS analog 8-anilinonaphtalene-1-sulfonate (ANS) can
interact with IL-1ra, affect its tertiary structure, and even
promote IL-1ra aggregation, these effects were achieved us-
ing a relatively high (4–21 mM) ANS concentration, and
at least equal or five times higher molar amounts of ANS
over the protein in the sample solution. Alternately, Latypov
et al. (42), using high-resolution NMR, found no evidence
for ANS-induced partially denatured or aggregated forms of
IL-1ra with lower (%0.5 mM) ANS concentrations.
The primary choice of tracers was driven by their different
modes of interaction with proteins, resulting in increases in
tracer fluorescent emission. Although bis-ANS acts as a gen-
eral hydrophobic surface probe (43), thioflavin T is a specific
probe for the pleated b-sheet conformation (44). Fig. 5
shows the OD450 aggregation profile of the protein, along
with the fluorescent traces of both dyes observed during their
coaggregation with IL-1ra at 47C. There is no detectable in-
crease of fluorescence during the lag phase (0–1100 s), indi-
cating that each dye selectively traces only the aggregation
process. The bis-ANS and OD450 traces are very similar in
showing two kinetic transitions. However, the second transi-
tion in the bis-ANS trace dominates, insofar as its fluorescent
signal is less likely to be influenced by the type I-type II
changes in aggregate cluster packing. Overall, the bis-ANS
tracer data correlate with the aggregation assay (OD450)
biphasic kinetic data, as well as with the difference in
amount of accumulated type I and type II aggregates
(Fig. 1 A). On the other hand, the change in fluorescence
Biophysical Journal 96(1) 199–208
203
204 Krishnan and RaibekasFIGURE 4 Scanning electron micrographs show morphology of IL-1ra aggregates collected at time points 1–5 (A–E). Magnification, 10,000. (A and B)
Time points 1 and 2 represent type I transition, and show average growth of aggregates from 0.5 to 1.0 mm diameter. (D and E) Time points 4 and 5 represent
type II transition, and demonstrate further aggregate growth up to 3.3-mm diameter. (C) Time point 3, with 1–1.5-mm diameter aggregates, represents midpoint
between transitions. A 2-mm scale bar is shown below D. See Results for more details.upon the coaggregation of thioflavin T shows a unique pro-
file, lacking the type I kinetic transition (Fig. 5). Thioflavin
T was shown to bind to nonnative b-sheet intermolecular
contacts in aggregates with a corresponding increase in fluo-
rescence (within a 480-nm region), and is used to track the
growth of amyloid fibrils (45,46). In the case of IL-1ra,
thioflavin T interacts exclusively with type II aggregates,
as indicated by the absence of the first transition in the fluo-
rescence kinetic trace. This is in agreement with the FTIR
Time (sec)
0 1000 2000 3000 4000 5000 6000
F
l
u
o
r
e
s
c
e
n
c
e
 
(
R
F
U
)
0
2000
4000
6000
8000
10000
12000
14000
16000
O
D
 
a
t
 
4
5
0
 
n
m
0.0
0.5
1.0
1.5
2.0
A
B
C
FIGURE 5 Dye-tracer aggregation kinetic profiles of 22 mg/mL IL-1ra in
CSE at 47C, as monitored by bis-ANS (curve A) and thioflavin T (curve B)
fluorescence. Ex ¼ 420 nm, and Em ¼ 500 nm (see Materials and Methods
for details). The OD450 trace (curve C) from Fig. 1 is shown as a reference.
Biophysical Journal 96(1) 199–208data and confirms that, unlike type I, the type II aggregates
are assembled via intermolecular b-sheet interactions. The
fluorescent tracer results clearly show the difference in struc-
tural nature of type I and type II aggregates, and support the
FTIR-observed aggregate structural transitions.
Effect of temperature and protein concentration
on IL-1ra aggregation rates
The aggregation kinetics of IL-1ra was dependent on protein
concentration and temperature increase. The first (type I) tran-
sition lag phase became shorter, suggesting a faster nucleation
event (47). This was followed by an overall faster first transi-
tion, a shorter first-transition termination phase (equal to the
type II lag phase), and finally, a faster second transition
(data not shown).
Fig. 6 A shows the aggregation-rate analysis of the
27-mg/mL protein assayed at 44–48C (317–321 K). The
kinetic rates (n) for the aggregation of both transitions
were determined as described in Materials and Methods,
using the integral method and plotted as a function of tem-
perature (K) (Fig. 6 A). Both transitions show a linear depen-
dence of aggregation rates on temperature but are different in
their slopes, indicating a higher first-transition rate constant.
Fig. 6 B illustrates the dependence of aggregation rates on
the initial protein concentration at constant temperature,
showing that at 47C, the aggregation rates of both transi-
tions gradually become higher as the concentration increases
Multistep Aggregation of IL-1ra 205from 12 to 20 mg/mL. The observed aggregation rates within
the same aggregate type were plotted against protein concen-
tration (Fig. 6 B), and the slope of the linear fitted ln-ln plot
was used to obtain the reaction order. It was estimated that
under our experimental conditions, the first (type I) transition
of aggregation was more of a second-order reaction (slope ¼
1.67), whereas the second (type II) transition clearly fol-
lowed a first-order reaction process (slope ¼ 1.06).
DISCUSSION
Previously (25), we investigated the aggregation of highly
concentrated (100–140 mg/mL) IL-1ra upon incubation at
39–42C, and the aggregation kinetic trace displayed a sin-
gle-transition (sigmoid) profile consisting of a prolonged
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FIGURE 6 Effect of temperature and protein concentration on IL-1ra ag-
gregation rates. IL-1ra is in CSE buffer, pH 6.5. (A) Observed aggregation
rates (n, unit/h) for first (circles) and second (triangles) transitions of aggre-
gation are plotted against temperature (K). Protein concentration is 27 mg/
mL. Error bar represents standard deviation of seven samples. (B) The ln-
ln plot of n (unit/h) versus protein molar concentration. Temperature is
47C. First (circles) and second (triangles) kinetic transition data are plotted
and linearly fitted, showing slope values of 1.67 and 1.06, respectively. Error
bar represents standard deviation of three samples. Dotted lines represent
95% confidence intervals for slopes. See Materials and Methods for exper-
imental details.lag phase, followed by phases of linear growth and plateau.
Here, we induced protein aggregation at lower (12–27 mg/mL)
protein concentrations and slightly higher (44–48C)
temperatures, without perturbing the protein secondary
structure (25,29). These new conditions led to a more com-
plex, biphasic kinetic behavior. In fact, when aggregates re-
sulting from the previously reported (25) single-transition ag-
gregation kinetic process were generated, isolated, and
subjected to FTIR and SEM analyses, they displayed proper-
ties of type I aggregates (data not shown). This indicates
that the type II aggregation transition can be largely sup-
pressed at certain combinations of protein concentration and
temperature.
Altogether, the kinetic, structural, and morphological data
suggest a multistep mechanism of thermally induced aggre-
gation of IL-1ra, as schematically depicted in Fig. 7. The ra-
tionale behind the mechanism steps is as follows. Previous
studies indicated that both protein aggregation and crystalli-
zation are nucleation-dependent kinetic processes that could
be intrinsically linked at an early stage preceding nucleus
formation (48,49). This could be the case for IL-1ra, because
the secondary structure of the crystal-packed protein is sim-
ilar to the structure of the protein packed in the early aggre-
gates (Fig. 2, A and B). The IL-1ra crystal cell unit contains
two protein molecules positioned such that they would form
an asymmetric dimer, perhaps because of the cation-pi inter-
actions linking them to the earlier, prenucleation stage of the
protein crystallization and aggregation kinetic processes
(25,33). Therefore, the IL-1ra asymmetric dimer-like assem-
bly stabilized by cation-pi interactions could be the earliest
intermolecular precursor of type I aggregation, as indicated
by the M* state (Fig. 7).
The aggregated protein undergoes a structural transition,
evidenced by loss of the 1942-cm1 high-frequency b-sheet
band and the appearance of the 1632-cm1 low-frequency
b-sheet band. Most striking is the conversion of the
1689-cm1 b-turn band and the formation of nonnative bands
at 1622 cm1 and 1692 cm1 (Fig. 2A). This may be concom-
itant with the property of the nucleation state shown in Fig. 8
as Ma, facilitating continuous growth of the type I aggregate
(Ma/Mb). The protein forms a clustered population of small
spheres that are ~0.2–0.5 mm in diameter (Fig. 4,A and B) and
that has native 1632-cm1 and nonnative 1622-cm1 IR
bands (Fig. 2 A). The type I aggregate population continues
to grow, developing spheres that, by the end of the third
time point, reach nearly 1.5 mm (Fig. 4C). The protein assem-
bly in aggregates at this stage is indicated by Mx on the
scheme. The secondary structure of the protein starts
showing significant changes as the low-frequency b-sheet
band at 1632 cm1 begins to shift to the nonnative 1622-cm1
band.
Consequently, the protein in the aggregates overcomes
a second energy barrier to form Mx*, resulting in a structural
rearrangement because of increased internal energy. This
structural transition forms a pseudonucleus with an altered,Biophysical Journal 96(1) 199–208
206 Krishnan and RaibekasFIGURE 7 Schematic drawing of proposed IL-1ra aggregation pathway at elevated temperatures. Monomer (M) and dimer (M*) are blue single and green
double circles, respectively. Both nucleus (Ma) and type I aggregates (Mb. Mx) are clusters of yellow circles. The rearrangement of type I aggregates into
a pseudonucleus (M*x) is indicated by red asterisk clusters. Type II aggregates (My . Mz) are asterisk-filled red circles. See Discussion for more details.possibly greater hydrophobic surface of aggregates, resulting
in favorable nonnative intermolecular contacts that initiate
type II aggregation. The type II growth phase may be prop-
agated in this way, resulting in a massive and cooperative
recruitment of protein molecules from solution as they are ef-
ficiently packed into the aggregate developing spheres (My).
The protein is tightly packed in the aggregates because of
a stronger intermolecular b-sheet signal, as evident in the
shift of IR bands to 1622 cm1 and 1694 cm1. The large
3–4-mm individual aggregates could be further developed
by the fusing of smaller aggregate spheres to some extent,
as seen in micrographs associated with the fourth and fifthtime points (Fig. 4, D and E) and as indicated by Mz species
in the scheme. Unlike the type I aggregation, the type II ag-
gregation appears to be a first-order reaction process (Fig. 6
B), suggesting direct protein self-assembly into a spherical
body.
The observed conformational flexibility of the type I
IL-1ra aggregates (Fig. 3) seems to be in accordance with
the aggregation behavior of some other b-sheet proteins.
For example, Cerda-Costa et al. (50) reported on the double
nature of very early aggregation kinetics of ADA2h, propos-
ing a step model of aggregation in which the denatured
polypeptide first folds into an aggregated b-intermediate,FIGURE 8 Crystal structure-based IL-1ra
surface analysis suggests an exposed b-sheet
with a hydrophobic channel. The surface distri-
bution was analyzed using a 3D Molecule
Viewer (Invitrogen, Carlsbad, CA) and the
Protein Data Bank coordinate file 1ILR. The
b-sheet is shown in red (right). The putative
hydrophobic channel is contributed by residues
W17, F149, F14, V49, L57, P51, and I52 (left).
Residue number accounts for the presence of an
extra N-terminal methionine in the recombinant
protein.
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Biophysical Journal 96(1) 199–208subsequently reorganizes into a more ordered b-sheet struc-
ture, and finally results in amyloid fiber formation. Serio
et al. (51) reported that the critical region of one prion pro-
tein, Sup35, is initially unstructured in solution, and then
forms self-seeded amyloid fibers. They examined the
in vitro mechanism by which this state is attained and repli-
cated. Structurally fluid oligomeric complexes appear to be
crucial intermediates in de novo amyloid nucleus formation.
Serio et al. (51) also observed that rapid assembly ensues
when these complexes conformationally convert upon asso-
ciation with nuclei.
Both aggregation kinetic transitions (and the first one in
particular) are sensitive to even slight increases in tempera-
ture (Fig. 6 A), supporting the idea of hydrophobic interac-
tions at play. The type I aggregates of IL-1ra observed in
our study bound only to bis-ANS, whereas type II aggregates
interacted with both bis-ANS and thioflavin T dyes (Fig. 5).
This indicates that type I population growth proceeds primar-
ily via hydrophobic interactions, whereas at an earlier,
prenucleation stage, electrostatic interactions can also play
a significant role (25). Type II aggregates can also be grown
by hydrophobic-driven packing, as indicated by increased
bis-ANS binding. At the same time, they are clearly distinc-
tive because of the intermolecular b-sheet hydrogen bonding
shown by both thioflavin T binding and the strong, nonna-
tive b-sheet bands observed using FTIR. This finding is in
agreement with the work of Chiti et al. (52) on the kinetic
partitioning of protein folding and aggregation of human
acylphosphatase, where a hydrophobic region with b-sheet
propensity appeared to be the major factor governing this
protein-aggregation process. In the case of IL-1ra, native-
like hydrophobic intermolecular interactions are possible as
the crystal structure-based surface analysis suggests at least
two putative hydrophobic clusters contributed by either W17
or W120 residues. As illustrated in Fig. 8, one of them,
a channel-like hydrophobic region, is indeed colocated with
the surface-exposed b-sheet.
The described biphasic aggregation kinetics of IL-1ra is
the most clearly defined example in protein aggregation.
Remarkably, it closely resembles a theoretical model for a bi-
logistic process of growth with sequential taxonomy (53).
Yet the question remains: why would IL-1ra aggregation
permit such sequential kinetic events? One plausible expla-
nation involves considering IL-1ra solution (any fixed com-
position, e.g., 22 mg/mL protein in CSE buffer) as a closed
thermodynamic system in its metastable equilibrium state
that can also permit two subsequent, lower-energy equilib-
rium states (54). Reaching each of those states would require
the system to undergo a partial liquid-to-solid phase transi-
tion, i.e., in our case, a protein aggregation. Upon an increase
in temperature, the system tends to overcome an energy-ac-
tivation barrier (nucleation) and reach a lower energy-equi-
librium state via a type I aggregation transition. However,
this new state in itself is a metastable one and, in turn, at
certain destabilizing conditions such as higher temperatures,could become a transient route toward reaching an even
lower energy-stable equilibrium state, via type II transition.
The necessity for a sequential type I/ type II mechanism
is driven by the favorable (for type II) activation energy
barrier provided by type I aggregate formation and its subse-
quent rearrangement (pseudonucleation). In this case, the en-
tire type I aggregation process could be viewed in itself
as a nucleation step for the type II aggregation of human
IL-1ra at elevated temperatures.
Taken together, our experimental data support the sequen-
tial type I/ type II mechanism. Still, the possibility of other
mechanisms should not be dismissed. For example, an alter-
native ‘‘parallel’’ model implies a kinetic, structural, and
thermodynamic uncoupling of the type II aggregation event,
presumably via a separate type I-independent nucleation
step. Future studies are needed to verify these hypotheses.
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